RevealDx
PrivateLast Round
Strategic
Aug 3, 2026
Est. Valuation
$34M
Total Funding Raised
$9.65M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
RevealDx operates in Healthcare & Life Sciences and is based in Seattle, Washington. Its latest recorded funding round was a Strategic round in August 2026.
RevealDx is a healthcare AI company that provides RevealAI-Lung, a software for the characterization of lung nodules from CT scans to improve diagnostic precision.
Sector
Healthcare & Life Sciences
Verticals
Medical Imaging, Medical AI, Healthcare Analytics, Precision Medicine
Business Model
B2B
Customer Profile
Subscription SaaS, Usage-Based SaaS
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
RevealDx Comparables
Compare RevealDx with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Optellum | 86% | |
| Riverain Technologies | 82% | |
| contextflow | 82% |
For institutional investors. Book with your work email.
RevealDx Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Aug 3, 2026 | ||||
| Series A | Jul 23, 2024 | ||||
| Private Placement | Mar 24, 2023 | ||||
| M&A | Mar 23, 2021 | ||||
| Seed | Dec 1, 2016 |
For institutional investors. Book with your work email.
RevealDx Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| A-Level Capital | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 3, 2026
$3.4M round led by 4DMedical Limited
- Nov 3, 2025
MDR Certification granted for RevealAI-Lung product.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- launchesNov 10, 2026
Reveal Dx announces RevealAI-Screen, a technology designed for lung cancer screening exams, in Washington on Nov 10th '26; availability is subject to FDA clearance and is expected in 2027.
- hiresNov 3, 2026
On Nov. 3rd '26 in Washington, Reveal Dx appoints David Austin as Vice President of Sales; he brings nearly 30 years of commercial leadership experience in diagnostic imaging, radiology, and medical technology commercialization.
For institutional investors. Book with your work email.
RevealDx Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about RevealDx's valuation, stock price, and market status.
Is RevealDx a public or private company?
RevealDx is a private company.
What is the current stock price of RevealDx?
RevealDx is a private company, so its shares have no public market price. Caplight tracks RevealDx's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is RevealDx worth (valuation)?
RevealDx's valuation is estimated at $34.0M based on funding round data.
Can I buy RevealDx stock?
RevealDx shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was RevealDx's last funding round?
RevealDx's most recent funding round was Strategic on August 3, 2026.
Who are the main investors in RevealDx?
Key investors in RevealDx include A-Level Capital.
Will RevealDx IPO soon?
No public IPO plans have been announced for RevealDx.
How can I track RevealDx secondary market activity?
Caplight tracks bids, offers, and trades in RevealDx's shares on secondary markets.